Now we're going to issue clear final guidance that those are not required. The uncertainty makes it difficult for drug developers, as you know, Zach, with capital markets, they want predictability. And so Knowing that now they [drug developers] can invest in a biosimilars development and have a timeframe of coming to market from being at the drawing board to actually coming to market of now two and a half to five years instead of five to eight years. And we think we can also shave off some of the time that it takes for the FDA to approve biosimilars. We've identified ways that we can streamline that process as we are with other drugs. (24:28–24:46)
CLAIM
Asserts that the development timeframe for biosimilars is now 2.5 to 5 years.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
_(cropped).png)